The term NMO spectrum disorders (NMOSD) was introduced to include AQP4-IgG seropositive patients with limited forms of NMO, and at risk of future attacks, as well as patients with cerebral, diencephalic, and brainstem lesions, or coexisting autoimmune disease (e.g., systemic lupus erythematosus [SLE] or Sjögren syndrome [SS]) [109]. The gene discussed is AQP4; the disease is systemic lupus erythematosus.